News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
His experience covers a wide range of areas including advisory services in the field of accounting, taxation, corporate and commercial laws, and regulatory matters
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Revenue from operations up 26% to Rs. 768 crores
The move will add new global talent to Cytel’s Strategic Consulting group
Subscribe To Our Newsletter & Stay Updated
